The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that there is no cause for concern of the risk of cancer for people with diabetes on insulin glargine (Lantus).
In June, studies published in 'Diabetologia', the Journal of the European Association for the Study of Diabetes, suggested there may be a small increased risk of cancer in those taking glargine as their only insulin.
The CHMP carried out an in-depth review of these studies and their outcomes. The studies were found to be inconclusive. In addition, the committee noted that the results of the studies were not consistent.